Lactobacillus oral microparticles capable of alleviating gastrointestinal discomfort

Abstract

The utility model provides a lactobacillus oral microparticle capable of relieving gastrointestinal discomfort, which comprises a plurality of lactobacillus bodies, the outer side of each lactobacillus body is coated with a defensive enzyme layer, and the outer side of each defensive enzyme layer is provided with an elastic layer; the lactobacillus body comprises lactobacillus particles, and the outer side of each lactobacillus particle is sequentially coated with an activity maintaining layer and an adsorption mucous membrane layer; according to the application, the adsorption mucous membrane layer is arranged, so that the intestinal mucous membrane adsorption capability of the lactobacillus particles can be improved, and the purpose of improving the survival rate of the lactobacillus particles in the particle structure is achieved; due to the arrangement of the enzyme resisting layer, the situation that lactobacillus particles are in contact with digestive enzymes in the stomach and damage lactobacillus bodies can be prevented, and the purpose of increasing the survival rate of the lactobacillus particles in the particle structure is further achieved; the survival rate of the lactobacillus granules can be increased, gastrointestinal discomfort can be better relieved, the structure is simple, manufacturing is easy, the production cost is low, and the effect of maintaining the activity of lactobacillus can be achieved.

Description

Technical Field

[0001] The present application relates to the field of oral particles, and in particular to a Lactobacillus oral particle capable of alleviating gastrointestinal discomfort. Background Art

[0002] Many probiotics have the effects of improving gastrointestinal flora and anti-inflammatory effects. Lactobacillus is one of them. With the development of society, more and more people use lactobacillus to replace drugs for gastrointestinal conditioning. In order to ensure the effectiveness of lactobacillus, it is necessary to ensure the high activity of lactobacillus. In the prior art, a layered particle structure is used.

[0003] For example, in the prior art, application number: 2017211301162, “Oral microparticles for maintaining high activity and stability of lactic acid bacteria”, comprises a lactic acid bacteria particle, an anti-dehydration layer coated on the outside of the lactic acid bacteria particle, an anti-damage layer coated on the outside of the anti-dehydration layer, an antioxidant layer coated on the outside of the anti-damage layer, an oligosaccharide layer coated on the outside of the antioxidant layer, and a polysaccharide layer coated on the outside of the oligosaccharide layer. The oral microparticles in this application have poor ability to adsorb intestinal mucosa and cannot prevent the digestive tract mycin in the stomach from damaging the lactic acid bacteria.

[0004] Therefore, it is necessary to provide a new technical solution to solve the above technical problems. Utility Model Content

[0005] The present application provides a lactobacillus oral microparticle capable of relieving gastrointestinal discomfort, comprising a plurality of lactobacillus bodies, the outer side of the lactobacillus bodies being coated with an enzyme resistance layer, and the outer side of the enzyme resistance layer being provided with an elastic layer.

[0006] As a preferred embodiment, the lactobacillus body comprises lactobacillus particles, and the outer side of the lactobacillus particles is sequentially coated with an activity-maintaining layer and an adsorption mucosal layer.

[0007] As a preferred solution, the active maintenance layer is made of any one of tomato juice, chlorella extract, peptone, beef extract, yeast powder, trypsin, glucose, trace minerals, and skimmed milk powder.

[0008] As a preferred embodiment, the adsorption mucosal layer adopts any one of vitamin A, vitamin C, vitamin D, vitamin E, yeast zinc, egg yolk powder, seaweed calcium, calcium carbonate, and calcium citrate.

[0009] As a preferred embodiment, the enzyme resistance layer adopts any one of sodium carbonate, sodium bicarbonate, arginine, potassium carbonate, potassium bicarbonate, catechin, green tea powder and green algae powder.

[0010] As a preferred embodiment, the elastic layer is made of any one of maltodextrin, corn starch, potato starch, microcrystalline cellulose, resistant dextrin, oat fiber and resistant starch.

[0011] In the present application, setting up an adsorption mucosal layer can increase the ability of lactobacillus particles to adsorb intestinal mucosa, thereby achieving the purpose of improving the survival rate of lactobacillus particles in the particle structure; and setting up an enzyme resistance layer can prevent lactobacillus particles from damaging lactobacillus bodies due to contact with digestive enzymes in the stomach, further achieving the purpose of improving the survival rate of lactobacillus particles in the particle structure; the present application can improve the survival rate of lactobacillus particles, thereby better alleviating gastrointestinal discomfort, has a simple structure, simple production, low production cost, and can achieve the effect of maintaining the activity of lactobacillus. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 It is a schematic diagram of the structure of this application;

[0013] Figure 2 It is a comparison chart of experimental data of this application;

[0014] 110. Lactobacillus particles; 120. Active maintenance layer; 130. Adsorption mucosal layer; 140. Enzyme resistance layer; 150. Elastic layer. DETAILED DESCRIPTION

[0015] The specific implementation of the present invention is described in detail below in conjunction with the accompanying drawings. It should be noted that the specific implementation described here is only used to illustrate and explain the present invention, and is not used to limit the present invention.

[0016] The present application provides a lactobacillus oral microparticle with the function of relieving gastrointestinal discomfort, comprising a plurality of lactobacillus bodies, wherein the lactobacillus bodies include lactobacillus particles 110, wherein the lactobacillus particles 110 are obtained by centrifugation and concentration after fermentation and culture of lactobacillus with various functions; the outer sides of the lactobacillus particles 110 are coated with an activity-maintaining layer 120 and an adsorption mucosal layer 130 in sequence; since the lactobacillus particles 110 are prone to lose water and enter a low-activity state under a low-temperature freeze-drying environment, coating with the activity-maintaining layer 120 can prevent the lactobacillus particles 110 from losing activity under long-term storage. In one embodiment of the present invention, the components of the activity-maintaining layer 120 are Any one of tomato juice, chlorella essence, peptone, beef extract, yeast powder, tryptone, glucose, trace minerals and skimmed milk powder is selected to maintain the active layer 120 to form a protective film on the surface of the lactobacillus particles 110; the adsorption mucosal layer 130 is coated on the outside of the active layer 120 to increase the ability of the lactobacillus particles 110 to adsorb intestinal mucosa, thereby achieving the purpose of improving the survival rate of the lactobacillus particles 110; the ingredients of the adsorption mucosal layer 130 are selected from any one of vitamin A, vitamin C, vitamin D, vitamin E, yeast zinc, egg yolk powder, seaweed calcium, calcium carbonate and calcium citrate.

[0017] The outer side of the lactobacillus body is coated with an enzyme resistance layer 140. More specifically, the enzyme resistance layer 140 is coated on the adsorption mucosal layer 130 and filled between the enzyme resistance layer 140 and the elastic layer 150. The setting of the enzyme resistance layer 140 can prevent the lactobacillus body from being damaged by the digestive enzyme in the stomach, thereby achieving the purpose of improving the survival rate of the lactobacillus particles 110 in the particle structure. The ingredients of the enzyme resistance layer 140 are selected from any one of sodium carbonate, sodium bicarbonate, arginine, potassium carbonate, potassium bicarbonate, catechins, green tea powder and green algae powder.

[0018] An elastic layer 150 is disposed on the outer side of the enzyme resistance layer 140. The elastic layer 150 is used to prevent the lactobacillus particles 110 from being damaged by the lactobacillus body due to the subsequent processing steps when being made into various dosage forms, thereby achieving the purpose of improving the survival rate of the lactobacillus. The elastic layer 150 is made of any one of maltodextrin, corn starch, potato starch, microcrystalline cellulose, resistant dextrin, oat fiber and resistant starch.

[0019] The present application provides an experimental method and experimental results of the lactobacillus having the function of alleviating gastrointestinal discomfort as follows:

[0020] Experimental Materials:

[0021] 1. Animals: female BALB / c mice (Lesco Biotech), 8 weeks old, 4 mice per group;

[0022] 2. Probiotics: Lactobacillus plantarum GMNL-141 oral microparticles;

[0023] 3. Enema-induced enteritis experiment:

[0024] DNBS (2,4-Dinitrobenzenesulfonic acid hydrate) was prepared with 30% EtOH to a final concentration of 2 mg / mouse.

[0025] Experimental methods:

[0026] 1. After entering the room, BALB / c mice were fed GMNL-141 oral microparticles every day for three weeks. The daily dose given to each mouse was 2*10^7cfu / mouse; the human dose is 4*10^9cfu / person / day. After three weeks of tube feeding of lactobacillus, the mice were subjected to an inflammatory bowel disease experiment. The mice were fasted for 5-6 hours before the disease experiment.

[0027] 2. The experimental groups were divided into control group (Ctrl, injected with 30% EtOH only); DNBS experimental control group (Sham) and DNBS + feeding probiotic oral microparticle structure group;

[0028] 3. After fasting, the mice were weighed and anesthetized with Zotai 50 and Rompun (2%). Each mouse (weighing about 20 g) was given 20 ul of the drug. When the depth of anesthesia reached a level where the mice had no reflex reactions, the drug was administered anally.

[0029] 4. Anal administration: 100ul of the drug is sucked into the anus by using a plastic hose (PE50) for animals. After applying vaseline on the catheter, it is inserted 4cm into the mouse anus, the anus is pressed, and 2mg of DNBS is slowly injected. The injection time is about 30-40 seconds. After the injection of the drug, the buttocks are raised. After waiting for about 1 minute, the mouse is kept in an inverted position for 3 minutes before the catheter is removed.

[0030] 5. Weigh the mice daily and observe their appearance. Sacrifice them two days later (~48 hrs) and observe the appearance and length of the intestines.

[0031] Experimental results:

[0032] like Figure 2 As shown, GMNL-141 oral microparticles can protect mice from weight loss caused by enteritis;

[0033] The experimental results showed that the weight of mice in the disease-induced group decreased significantly, while the weight of mice in the group fed with GMNL-141 oral microparticles did not change much and was close to the trend of the control group, indicating that feeding GMNL-141 has the ability to protect mice from maintaining normal body weight, reduce intestinal inflammation and restore normal physiological state.

[0034] The experimental results showed that feeding mice with GMNL-141 oral microparticles could protect the shortening of intestinal segments caused by enteritis. The intestinal appearance and length of mice fed with GMNL-141 oral microparticles were significantly improved compared with the DNBS group, indicating that feeding GMNL-141 has the effect of protecting the intestines from returning to normal and reducing inflammation.

[0035] Conclusion: The results of the inflammatory bowel disease animal model experiment showed that feeding GMNL-141 oral microparticles improved the weight loss and relieved intestinal inflammation caused by inflammatory bowel disease, allowing mice to return to normal physiological state compared with the disease-creating group (DNBS).

[0036] In the present application, setting up an adsorption mucosal layer can increase the ability of lactobacillus particles to adsorb intestinal mucosa, thereby achieving the purpose of improving the survival rate of lactobacillus particles in the particle structure; and setting up an enzyme resistance layer can prevent lactobacillus particles from damaging lactobacillus bodies due to contact with digestive enzymes in the stomach, further achieving the purpose of improving the survival rate of lactobacillus particles in the particle structure; the present application can improve the survival rate of lactobacillus particles, thereby better alleviating gastrointestinal discomfort, has a simple structure, simple production, low production cost, and can achieve the effect of maintaining the activity of lactobacillus.

[0037] The present invention has been described through the above-mentioned relevant embodiments, however, the above-mentioned embodiments are only examples for implementing the present invention; it must be pointed out that the disclosed embodiments do not limit the scope of the present invention. On the contrary, modifications and equivalent settings contained in the spirit and scope of the claims are all included in the scope of the present invention.

Claims

1. A lactobacillus oral microparticle having the function of alleviating gastrointestinal discomfort, comprising a plurality of lactobacillus bodies, characterized in that: The outer side of the lactobacillus body is coated with an enzyme resistance layer (140), and the outer side of the enzyme resistance layer (140) is provided with an elastic layer (150).

2. The Lactobacillus oral microparticles for alleviating gastrointestinal discomfort according to claim 1, characterized in that: The lactobacillus body comprises a lactobacillus particle (110), and the outer side of the lactobacillus particle (110) is sequentially coated with an activity-maintaining layer (120) and an adsorption mucosal layer (130).

3. The Lactobacillus oral microparticles for alleviating gastrointestinal discomfort according to claim 2, characterized in that: The active maintenance layer (120) is made of any one of tomato juice, chlorella extract, peptone, beef extract, yeast powder, trypsin, glucose, trace minerals, and skimmed milk powder.

4. The Lactobacillus oral microparticles for alleviating gastrointestinal discomfort according to claim 2, characterized in that: The adsorption mucosal layer (130) is made of any one of vitamin A, vitamin C, vitamin D, vitamin E, yeast zinc, egg yolk powder, seaweed calcium, calcium carbonate, and calcium citrate.

5. The Lactobacillus oral microparticles for alleviating gastrointestinal discomfort according to claim 1, characterized in that: The enzyme resistance layer (140) is made of any one of sodium carbonate, sodium bicarbonate, arginine, potassium carbonate, potassium bicarbonate, catechin, green tea powder and green algae powder.

6. The Lactobacillus oral microparticles for alleviating gastrointestinal discomfort according to claim 1, characterized in that: The elastic layer (150) is made of any one of maltodextrin, corn starch, potato starch, microcrystalline cellulose, resistant dextrin, oat fiber and resistant starch.

Images